Just One Gene May Explain Why Most Alzheimer’s Disease Ever Happens

Alzheimer’s disease is often described as a tangled web of genetics, aging, lifestyle, and chance. With no cure and only modestly effective treatments, the prevailing view has been that the disease arises from many small influences stacking up over a lifetime.

But what if that picture is wrong?

A new international study suggests that most Alzheimer’s disease may hinge on something far simpler and far more sobering: the version of a single gene that nearly everyone carries.

The gene is called APOE, short for apolipoprotein E. It has long been known to influence Alzheimer’s risk, but the scale of its impact has remained controversial. Now, by pooling data from multiple massive studies and using a rare genetic reference group, researchers estimate that without the risk-linked forms of APOE, Alzheimer’s disease would be uncommon and perhaps even rare.

That conclusion forces a rethink of how Alzheimer’s develops and how it might ultimately be prevented.

The Gene That Has Haunted Alzheimer’s Research for 30 Years

APOE has been part of the Alzheimer’s conversation since the early 1990s. The gene comes in three common forms, known as ε2, ε3, and ε4. Every person inherits two copies.

Most people carry at least one ε3, the most common variant worldwide. Around one in four people carries at least one ε4, which has long been associated with sharply increased Alzheimer’s risk. A small minority carry ε2, a version linked to lower risk and delayed disease onset.

For years, ε4 dominated the spotlight. It was framed as the “bad” Alzheimer’s gene, while ε3 was treated as neutral and ε2 as protective. But this framing masked a deeper issue.

Neutral compared to what?

Until now, most studies compared ε4 carriers to people with ε3, not to those with the lowest-risk genotype. That choice made sense statistically, but it underestimated how much risk ε3 itself carries.

This new study takes a different approach.

Why ε2 Homozygotes Change the Picture

To understand how much disease is truly attributable to a risk factor, researchers must compare it to the lowest possible baseline. In this case, that means people who inherited ε2 from both parents, a rare group making up well under 1 percent of most populations.

These individuals have exceptionally low rates of Alzheimer’s pathology, even late in life. By using them as the reference group, researchers could calculate how much Alzheimer’s and dementia would disappear if everyone had similarly low genetic risk.

That question required enormous datasets, because ε2 homozygotes are so uncommon. To solve it, the researchers analyzed four major sources of evidence.

Nearly Half a Million Lives, Examined From Every Angle

The analysis drew on data from about 470,000 participants across four independent studies.

Two population biobanks, the UK Biobank and FinnGen, provided genetic data linked to long-term health records for people aged 60 and older. These datasets captured clinically diagnosed Alzheimer’s disease and all-cause dementia in real-world populations.

A third dataset came from the A4 Study, a clinical trial focused on cognitively normal older adults. Instead of diagnoses, this study used brain scans to detect amyloid-beta buildup, a hallmark of Alzheimer’s pathology that can appear years before symptoms.

Finally, the team reanalyzed data from the Alzheimer’s Disease Genetics Consortium, which included autopsy-confirmed Alzheimer’s cases compared to people whose brains showed no Alzheimer’s pathology.

Each dataset approached Alzheimer’s from a different angle, diagnosis, biology, and neuropathology. All pointed to the same conclusion.

The Shockingly Large Role of Common APOE Variants

Across studies, the researchers calculated something called a population attributable fraction. In simple terms, it estimates what proportion of disease cases would not occur if a specific risk factor were absent.

The results were striking.

Between 70 and more than 90 percent of Alzheimer’s disease cases were attributable to the combined effects of the ε3 and ε4 variants of APOE. In the autopsy-confirmed dataset, the estimate exceeded 90 percent.

Even more surprising was the role of ε3 itself. While ε4 carried the greatest individual risk, ε3 was responsible for a large share of cases simply because almost everyone carries it. When compared to ε2 homozygotes, ε3 significantly increased Alzheimer’s risk and contributed roughly a third of the total disease burden.

In contrast, the proportion of all-cause dementia attributable to APOE was lower but still substantial, at around 45 percent. This makes sense, as not all dementia is caused by Alzheimer’s pathology.

Taken together, the findings suggest that without the genetic risk introduced by ε3 and ε4, Alzheimer’s disease would be dramatically less common.

Why This Does Not Mean Alzheimer’s Is a “Single-Gene Disease”

At first glance, the results sound almost heretical. Alzheimer’s is not monogenic, and the researchers are careful to stress this point.

Many factors still contribute to disease development, including age, vascular health, inflammation, and possibly environmental exposures. What the study shows is not that APOE alone causes Alzheimer’s, but that it is a dominant component cause.

In other words, other risk factors matter far less in the absence of APOE-related vulnerability. Without that underlying susceptibility, most people may never reach the threshold where Alzheimer’s pathology takes hold.

This idea helps explain why decades of research targeting amyloid plaques have produced limited clinical benefits. If APOE shapes how amyloid forms, spreads, and damages neurons, then intervening downstream may be too late or too indirect.

A New Lens on Amyloid and Brain Degeneration

The A4 Study adds an important layer to the story. Among cognitively normal older adults, amyloid buildup in the brain was overwhelmingly concentrated in people carrying ε3 or ε4.

Very few ε2 homozygotes showed amyloid positivity on brain scans, and even then, the burden appeared lower than in other groups. This reinforces the idea that APOE variants influence Alzheimer’s long before symptoms appear.

Rather than amyloid being the first domino to fall, APOE may determine whether the dominoes are even set up.

Why APOE Stands Apart From Other Alzheimer’s Genes

To put APOE’s impact into perspective, the researchers compared it to other genetic risk loci identified through genome-wide association studies.

No other Alzheimer’s-related genetic region came close. Even when multiple genes were considered together, none approached the population impact of APOE.

This level of dominance is rare among complex diseases. It underscores how unusual Alzheimer’s is compared to conditions like heart disease, where risk is spread across dozens of pathways with overlapping effects.

The Limits of the Findings

As sweeping as the results are, they come with important caveats.

Most participants were of European ancestry, and APOE’s effects vary across populations. The estimates may not fully generalize to other ethnic groups.

The rarity of ε2 homozygotes also introduces uncertainty. When reference groups are small, confidence intervals widen. Still, the consistency across four very different datasets strengthens confidence in the overall conclusion.

Finally, population attributable fractions assume a causal relationship, an assumption that is unusually safe for genetic variants but still worth acknowledging.

What This Means for Prevention and Treatment

If APOE lies at the heart of Alzheimer’s disease, then targeting it directly could have outsized benefits.

Yet fewer than 1 percent of Alzheimer’s therapies currently in clinical trials aim at APOE itself. Most continue to focus on amyloid or tau, downstream consequences rather than upstream drivers.

The new findings argue for a strategic shift. Gene therapies, protein-modifying drugs, immunotherapies, and molecular correctors that alter APOE function could, in theory, prevent or delay most Alzheimer’s cases.

That does not mean abandoning other approaches. But it does suggest that without addressing APOE, progress will remain limited.

A Reframing of Alzheimer’s Risk

Perhaps the most unsettling implication of the study is this: for most people, Alzheimer’s risk is not evenly distributed across the population. It is inherited early, long before memory fades or brain scans change.

The flip side is hope. If the primary driver of Alzheimer’s can be identified, understood, and modified, prevention may one day be possible on a scale previously unimagined.

For a disease that has resisted nearly every therapeutic advance, that reframing alone is a profound step forward.

The research was published in npj Dementia on January 09, 2026.